• No se han encontrado resultados

UHPLC ESI ORBITRAP MS analysis of the native Mapuche medicinal plant palo negro (Leptocarpha rivularis DC –Asteraceae) and evaluation of its antioxidant and cholinesterase inhibitory properties

N/A
N/A
Protected

Academic year: 2020

Share "UHPLC ESI ORBITRAP MS analysis of the native Mapuche medicinal plant palo negro (Leptocarpha rivularis DC –Asteraceae) and evaluation of its antioxidant and cholinesterase inhibitory properties"

Copied!
10
0
0

Texto completo

Loading

Figure

Table 2. Content of phenolics and antioxidant capacities of L. rivularis extracts evidenced as the bleaching of the DPPH and ABTS radicals, FRAP (ferric reducing anti- anti-oxidant power), SA (superoxide anion scavenging capacity), Total Phenolic Content (

Referencias

Documento similar

The draft amendments do not operate any more a distinction between different states of emergency; they repeal articles 120, 121and 122 and make it possible for the President to

H I is the incident wave height, T z is the mean wave period, Ir is the Iribarren number or surf similarity parameter, h is the water depth at the toe of the structure, Ru is the

Since such powers frequently exist outside the institutional framework, and/or exercise their influence through channels exempt (or simply out of reach) from any political

Of special concern for this work are outbreaks formed by the benthic dinoflagellate Ostreopsis (Schmidt), including several species producers of palytoxin (PLTX)-like compounds,

In the previous sections we have shown how astronomical alignments and solar hierophanies – with a common interest in the solstices − were substantiated in the

In the second section, the Chua circuit is described; and in the one that follows, it quantifies the chaotic dynamics of the Vc l (x 1 ) signal of the circuit in question with

These networks based on metric learning techniques improve clustering and classification results over traditional categorical cross-entropy loss networks for plant

Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre,